Search Results
Search for other papers by Matteo Scopel in
Google Scholar
PubMed
Search for other papers by Eugenio De Carlo in
Google Scholar
PubMed
Search for other papers by Francesca Bergamo in
Google Scholar
PubMed
Search for other papers by Sabina Murgioni in
Google Scholar
PubMed
Search for other papers by Riccardo Carandina in
Google Scholar
PubMed
Search for other papers by Anna Rita Cervino in
Google Scholar
PubMed
Search for other papers by Marta Burei in
Google Scholar
PubMed
Search for other papers by Federica Vianello in
Google Scholar
PubMed
Search for other papers by Vittorina Zagonel in
Google Scholar
PubMed
Search for other papers by Matteo Fassan in
Google Scholar
PubMed
Search for other papers by Roberto Vettor in
Google Scholar
PubMed
in both these groups the relationship between bone metastases, primary type/site of NET, laboratory parameters (chromogranin A (CgA), calcium, phosphate, parathyroid hormone (PTH) and vitamin D) and proliferation markers (Ki-67 and mitotic index
Search for other papers by Malgorzata Fuksiewicz in
Google Scholar
PubMed
Search for other papers by Maria Kowalska in
Google Scholar
PubMed
Search for other papers by Agnieszka Kolasinska-Cwikla in
Google Scholar
PubMed
Search for other papers by Beata Kotowicz in
Google Scholar
PubMed
diagnosis, the determination of NSE, as well as chromogranin A (CgA), assists in the diagnosis and treatment monitoring of patients ( 15 , 16 , 17 ). Both markers are classified as so-called non-specific markers, released by different tumours regardless
Search for other papers by Carole Morin in
Google Scholar
PubMed
Search for other papers by Keo-Morakort Benedetto in
Google Scholar
PubMed
Centre de Recherche en Cancérologie de Lyon, UMR Inserm 1052 CNRS 5286, Lyon Cedex 08, France
Search for other papers by Agathe Deville in
Google Scholar
PubMed
University of Lyon, Université Lyon 1, France
Search for other papers by Laurent Milot in
Google Scholar
PubMed
Search for other papers by Aurélie Theillaumas in
Google Scholar
PubMed
University of Lyon, Université Lyon 1, France
Hospices Civils de Lyon, Institut de Pathologie Est, Bron Cedex, France
Search for other papers by Valérie Hervieu in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Edouard Herriot, Gastroentérologie, Lyon Cedex 03, France
Search for other papers by Mathieu Pioche in
Google Scholar
PubMed
University of Lyon, Université Lyon 1, France
Hospices Civils de Lyon, Hôpital Edouard Herriot, Chirurgie Digestive, Lyon Cedex 03, France
Search for other papers by Gilles Poncet in
Google Scholar
PubMed
Search for other papers by Julien Forestier in
Google Scholar
PubMed
Search for other papers by Laurent François in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Louis Pradel, Endocrinologie, Bron Cedex, France
Search for other papers by Francoise Borson-Chazot in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Edouard Herriot, Chirurgie Digestive, Lyon Cedex 03, France
Search for other papers by Mustapha Adham in
Google Scholar
PubMed
Search for other papers by Catherine Lombard-Bohas in
Google Scholar
PubMed
Centre de Recherche en Cancérologie de Lyon, UMR Inserm 1052 CNRS 5286, Lyon Cedex 08, France
University of Lyon, Université Lyon 1, France
Search for other papers by Thomas Walter in
Google Scholar
PubMed
-up and the initial treatments was defined according to ENETS guidelines (French guidelines are similar) ( 3 , 6 ). Minimal work-up included laboratory test (chromogranin A), endoscopy along with endoscopic ultrasound (EUS), imaging (CT scan, MRI, and